The U.S. FDA has approved the supplemental Biologics License Application (sBLA) for Amgen’s BLINCYTO (blinatumomab) for the treatment of adults and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in first or second complete remission with minimal residual disease (MRD), based on additional data from two Phase 3 studies. The approval converts BLINCYTO’s accelerated approval to a full approval. Amgen continues to advance its development program ...